Symbiotec Q1 FY27: 7% revenue growth, guides 20-25% for FY27
SYMBIOTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Symbiotec filed Q1 FY27 earnings call transcript. Revenue rose 7% YoY to INR 218 cr, with API at INR 215 cr and 60%+ gross margins. API EBITDA hit INR 66 cr (+9%). Consolidated EBITDA was INR 45 cr and PAT INR 14 cr, hit by INR 23 cr opex and INR 11 cr depreciation from new businesses. Management guides FY27 revenue growth of 20% and EBITDA growth of 25%, plus or minus 5%. Disclosed long-term take-or-pay CDMO and DCV contracts, with new revenues expected in 6 to 12 months.
FY27 guidance of 20% revenue and 25% EBITDA growth plus disclosed long-term contracts support growth outlook. Near-term earnings weighed by new business expenses.